Homology Medicines Inc.

6.48-0.3300-4.85%Vol 466.91K1Y Perf -51.49%
Apr 19th, 2021 12:03 DELAYED
BID6.48 ASK6.49
Open6.75 Previous Close6.81
Pre-Market- After-Market-
 - -%  - -
Target Price
26.33 
Analyst Rating
Strong Buy 1.20
Potential %
304.46 
Finscreener Ranking
★★★★★     61.24
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★+     54.06
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     70.88
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap327.16M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
0.09 
Earnings Date
6th May 2021

Today's Price Range

6.476.76

52W Range

6.4717.34

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-6.97%
1 Month
-33.56%
3 Months
-47.37%
6 Months
-37.81%
1 Year
-51.49%
3 Years
-67.53%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
FIXX6.48-0.3300-4.85
AAPL134.11-0.0500-0.04
GOOG2 293.56-4.2000-0.18
MSFT258.47-2.2700-0.87
XOM56.26-0.4000-0.71
WFC44.060.22000.50
JNJ162.790.55000.34
FB302.15-4.0300-1.32
GE13.36-0.0300-0.22
JPM153.15-0.1500-0.10
Financial StrengthValueIndustryS&P 500US Markets
9.60
9.70
0.06
0.08
-
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
-
-5 515.10
-5 181.30
-
-
RevenueValueIndustryS&P 500US Markets
2.11M
0.04
31.94
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.65-0.624.62
Q03 2020-0.81-0.6223.46
Q02 2020-0.81-0.783.70
Q01 2020-0.76-0.78-2.63
Q04 2019-0.72-0.5523.61
Q03 2019-0.58-0.67-15.52
Q02 2019-0.54-0.61-12.96
Q01 2019-0.55-0.64-16.36
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.659.72Positive
6/2021 QR-0.694.17Positive
12/2021 FY-2.810.00-
12/2022 FY-2.65-356.90Negative
Next Report Date6th May 2021
Estimated EPS Next Report-0.65
Estimates Count5
EPS Growth Next 5 Years %44.30
Volume Overview
Volume466.91K
Shares Outstanding50.49M
Trades Count2.53K
Dollar Volume4.49M
Avg. Volume541.87K
Avg. Weekly Volume980.31K
Avg. Monthly Volume978.43K
Avg. Quarterly Volume582.08K

Homology Medicines Inc. (NASDAQ: FIXX) stock closed at 6.81 per share at the end of the most recent trading day (a -3.13% change compared to the prior day closing price) with a volume of 910.04K shares and market capitalization of 327.16M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 206 people. Homology Medicines Inc. CEO is Arthur O. Tzianabos.

The one-year performance of Homology Medicines Inc. stock is -51.49%, while year-to-date (YTD) performance is -39.68%. FIXX stock has a five-year performance of %. Its 52-week range is between 6.47 and 17.34, which gives FIXX stock a 52-week price range ratio of 0.09%

Homology Medicines Inc. currently has a PE ratio of -2.70, a price-to-book (PB) ratio of 1.93, a price-to-sale (PS) ratio of 171.24, a price to cashflow ratio of 57.40, a PEG ratio of 2.32, a ROA of -42.77%, a ROC of -54.78% and a ROE of -53.91%. The company’s profit margin is -%, its EBITDA margin is -5 181.30%, and its revenue ttm is $2.11 Million , which makes it $0.04 revenue per share.

Of the last four earnings reports from Homology Medicines Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.65 for the next earnings report. Homology Medicines Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Homology Medicines Inc. is Strong Buy (1.2), with a target price of $26.33, which is +304.46% compared to the current price. The earnings rating for Homology Medicines Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Homology Medicines Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Homology Medicines Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 19.79, ATR14 : 0.72, CCI20 : -106.41, Chaikin Money Flow : -0.29, MACD : -1.45, Money Flow Index : 14.45, ROC : -26.62, RSI : 31.95, STOCH (14,3) : 7.65, STOCH RSI : 0.58, UO : 39.63, Williams %R : -92.35), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Homology Medicines Inc. in the last 12-months were: Albert Seymour (Sold 25 000 shares of value $295 287 ), Kush M. Parmar (Sold 1 000 000 shares of value $12 535 914 ), Timothy P. Kelly (Option Excercise at a value of $49 683), Timothy P. Kelly (Sold 11 768 shares of value $147 323 ), W. Bradford Smith (Option Excercise at a value of $8 640), W. Bradford Smith (Sold 13 500 shares of value $192 425 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (80.00 %)
5 (83.33 %)
5 (83.33 %)
Moderate Buy
1 (20.00 %)
1 (16.67 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
1 (16.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.20
Strong Buy
1.17
Strong Buy
1.33

Homology Medicines Inc.

Homology Medicines Inc is an US based is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

CEO: Arthur O. Tzianabos

Telephone: +1 781 301-7277

Address: One Patriots Park, Bedford 01730, MA, US

Number of employees: 206

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

67%33%

Bearish Bullish

56%44%

News

Stocktwits